5.39  -0.2 (-3.58%)		10-30 16:00
Open: 5.54 High: 5.59 Volume: 100,724		Pre. Close: 5.59 Low: 5.39 Market Cap: 109(M)

Short term
Mid term
Targets	6-month :	6.82	1-year :	7.96
Resists	First :	5.84	Second :	6.82
Pivot price	5.17
Supports	First :	5.07	Second :	4.61
MAs	MA(5) :	5.56	MA(20) :	5.14
	MA(100) :	4.97	MA(250) :	4.57
MACD	MACD :	0.1	Signal :	0
%K %D	K(14,3) :	80.4	D(3) :	89.3
RSI	RSI(14): 54.6
52-week	High :	5.84	Low :	3.5

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PYPD ] has closed below upper band by 33.5%. Bollinger Bands are 38.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.6 - 5.63	5.63 - 5.65
Low:	5.32 - 5.35	5.35 - 5.39
Close:	5.33 - 5.39	5.39 - 5.44

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

Thu, 29 Oct 2026
A webcast will cover PolyPid's business operations at 8:30 a.m. Nov. 11. - Stock Titan

Wed, 28 Oct 2026
A drug candidate designed to keep antibiotics in wounds for weeks joins PolyPid (PYPD)'s pipeline. - Stock Titan

Tue, 27 Oct 2026
PolyPid stock gains new Outperform at Oppenheimer (PYPD:NASDAQ) - Seeking Alpha

Fri, 23 Oct 2026
PolyPid Ltd. Estimates – NASDAQ:PYPD - TradingView

Fri, 09 Oct 2026
PolyPid Ltd. (PYPD) Gets EMA MAA Validation, Reclaims EU Rights for D-PLEX100 - TradingView

Wed, 12 Aug 2026
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	20 (M)
Shares Float	12 (M)
Held by Insiders	12.3 (%)
Held by Institutions	34.5 (%)
Shares Short	126 (K)
Shares Short P.Month	195 (K)

EPS	-1.45
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-74.7 %
Return on Equity (ttm)	-243.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.49
Qtrly Earnings Growth	0 %
Operating Cash Flow	-29 (M)
Levered Free Cash Flow	-17 (M)

PE Ratio	-3.75
PEG Ratio	0
Price to Book value	20.73
Price to Sales	0
Price to Cash Flow	-3.78

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.